A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)
A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib
Sponsor: Celgene
Terminated
Slow accrual.
Other terminated trials from Celgene
Other Myelofibrosis trials with similar outcome
A PHASE3 clinical study on Myelofibrosis and Post-Polycythemia Vera Myelofibrosis, this trial is terminated or withdrawn. The trial is conducted by Celgene and has accumulated 30 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
30 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Jan 2025 — Sep 2025 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 25 earlier versions
-
Jul 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Nov 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Sep 2021 — Mar 2022 [monthly]
Recruiting PHASE3
-
Feb 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE3
-
May 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
Mar 2020 — May 2020 [monthly]
Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Jan 2020 [monthly]
Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Mar 2019 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
- Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
For direct contact, visit the study record on ClinicalTrials.gov .